

**nnit**



Aug 14, 2018 09:02 CEST

# **NNIT and ValGenesis Partner on Cloud-Based Validation Software for the Life Sciences Industry**

**Copenhagen, August 14, 2018** – NNIT, a leading provider of IT services and consultancy, announces a strategic partnership with ValGenesis Inc., a pioneer in paperless validation software systems.

Validation activities in the life-sciences sector are still almost entirely manual and paper-based, and the process is usually inefficient, costly and prone to error. As the global leader in Enterprise Validation Lifecycle Management Solutions (VLMS), ValGenesis enables companies to manage their entire IT validation lifecycle electronically.

The cloud-based ValGenesis solution helps life sciences companies eliminate the use of paper and remove the inefficiencies that plague today's IT validation processes. It enables rigorous compliance, helps to address data integrity concerns, improve consistency and reduce validation cycle time significantly.

“We partner with the first mover in this niche area to help more life sciences companies say goodbye to paper,”

says Bo Olsen, General Manager, NNIT US. He continues:

“ValGenesis’ software is developing into a de-facto standard on how validation should be assured and managed because companies adopting ValGenesis are realizing significant improvement (consistency, compliance and cycle time reduction) in their validation processes.”

As the preferred global partner to ValGenesis, NNIT will integrate the paperless validation software within its suite of services for the pharmaceutical and biotech industry. The training and cooperative efforts will focus on NNIT's 200+ validation consultants and sales force in Europe.

The two companies already have good experience working together in the US market, where ValGenesis’ software has been implemented by ten out of the top 20 pharmaceutical companies.

“Not only does ValGenesis allow life sciences companies to manage their validation processes electronically; it significantly reduces the validation cycle time and cost, eliminates potential data integrity issues in the validation process, enables standardization and enforces consistency and compliance in the corporate validation process. We look forward to expanding our footprint and provide top-notch local support to our customers by partnering with NNIT, a leading provider of IT services and consultancy to the global life sciences industry with exceptionally strong positions in Europe and China,” explains Siva Samy, Ph.D., CEO at ValGenesis.

NNIT has approximately 400 clients of which around 150 are located outside Denmark. Some 20% are international life sciences clients (June 2018).

## More information

Helga Heyn, NNIT Communications, +45 30 77 81 41, [hhey@nnit.com](mailto:hhey@nnit.com).

Shanti Mulyadi, ValGenesis – Communication, Ph: 510 445 0505 Ex. 1015, [Shanti.mulyadi@valgenesis.com](mailto:Shanti.mulyadi@valgenesis.com).

---

NNIT is an international consultancy in the development, implementation, validation and operation of IT for the life sciences industry. We create value for our clients by treating their IT as if it was our own. And of course we meet the industry's strictest regulatory requirements. We apply the latest advances in technology to make our clients' software, business processes and communication more effective. As of June 2018, NNIT A/S had 3,122 employees. For more information please visit [www.nnit.com](http://www.nnit.com).

## About ValGenesis

[ValGenesis, Inc.](http://www.valgenesis.com) is the inventor of an innovative software platform serving as the foundation for managing compliance-based validation activities in Life Sciences companies. ValGenesis, Inc. provides the first enterprise application to manage the corporate validation lifecycle process. As the only system for managing validation execution and approval 100% electronically, ValGenesis was selected by an industry peer review committee to receive the Parenteral Drug Association (PDA) New Innovative Technology Award. The solution is fully compliant with U.S. FDA 21 CFR Part 11 and Annex 11 requirements. For more information, visit [www.valgenesis.com](http://www.valgenesis.com).

## Contacts



### **Tina Joanne Hindsbo**

Press Contact

Media Relations Manager

[tnjh@nnit.com](mailto:tnjh@nnit.com)

+45 3077 9578



**Kasper Ortvald Larsen**

Press Contact

Communications Consultant

[kpoa@nnit.com](mailto:kpoa@nnit.com)

+45 3077 9465